Table 2.
The prevalence of inflammatory and structural lesions at T0 and T24 in three cohorts (axSpA imaging arm, axSpA clinical ± imaging arm, not full ASAS axSpA).
| T0 MRI evaluation | |||
|---|---|---|---|
| axSpA imaging arm | axSpA clinical ± imaging arm | Not full ASAS axSpA | |
| Total number of patients | 21 (28%) | 29 (38.7%) | 25 (33.3%) |
| SIJ total lesions | 21 (100%) | 27 (93.1%) | 4 (16%) |
| BMO lesions | 21 (100%) | 27 (93.1%) | 0 (0%) |
| Sclerosis lesions | 10 (47.6%) | 14 (48.28%) | 0 (0%) |
| Fatty lesions | 7 (33.3%) | 2 (6.9%) | 4 (16%) |
| Erosions lesions | 8 (38.1%) | 3 (10.3%) | 0 (0%) |
| Spine total lesions | 20 (95.2%) | 19 (65.5%) | 11 (44%) |
| BMO lesions | 18 (85.7%) | 15 (51.7%) | 9 (36%) |
| Enthesitis lesions | 17 (80.9%) | 19 (65.5%) | 11 (44%) |
| Fatty lesions | 6 (28.6%) | 7 (24.1%) | 4 (16%) |
| Sclerosis/syndesmophytes lesions | 6 (28.6%) | 6 (20.7%) | 3 (12%) |
| Erosions lesions | 2 (9.5%) | 2 (6.9%) | 1 (4%) |
| T24 MRI evaluation | |||
| axSpA imaging arm | axSpA clinical ± imaging arm | Not full ASAS axSpA | |
| Total number of patients | 16 (29.6%) | 22 (40.7%) | 16 (29.6%) |
| SIJ total lesions | 16 (100%) | 15 (68.2%) | 1 (6.3%) |
| BMO lesions | 9 (56.3%) | 13 (59.1%) | 0 (0%) |
| Sclerosis lesions | 7 (43.8%) | 10 (45.5%) | 0 (0%) |
| Fatty lesions | 6 (37.5%) | 4 (18.2%) | 1 (6.3%) |
| Erosions lesions | 3 (18.8%) | 2 (9.1%) | 0 (0%) |
| Spine total lesions | 11 (68.8%) | 4 (18.2%) | 7 (43.8%) |
| BMO lesions | 7 (43.8%) | 5 (22.7%) | 5 (31.3%) |
| Enthesitis lesions | 7 (43.8%) | 6 (27.3%) | 7 (43.8%) |
| Fatty lesions | 6 (37.5%) | 4 (18.2%) | 4 (25%) |
| Sclerosis/syndesmophytes lesions | 7 (43.8%) | 3 (13.6%) | 2 (12.5%) |
| Erosions lesions | 1 (6.3%) | 2 (9.1%) | 0 (0%) |
MRI, magnetic resonance imaging; SIJ, sacroiliac joints; BMO, bone marrow oedema; axSpA, Axial Spondyloarthritis; T0, 0 months; T24, 24 months.